Avantor, Inc. (NYSE:AVTR) Shares Purchased by Norris Perne & French LLP MI

Norris Perne & French LLP MI increased its position in shares of Avantor, Inc. (NYSE:AVTR) by 2.8% during the first quarter, Holdings Channel.com reports. The fund owned 480,117 shares of the company’s stock after acquiring an additional 13,047 shares during the quarter. Norris Perne & French LLP MI’s holdings in Avantor were worth $12,277,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. Fifth Third Bancorp increased its stake in Avantor by 125.3% in the 4th quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock worth $28,000 after purchasing an additional 694 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its position in Avantor by 565.5% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock worth $30,000 after acquiring an additional 1,131 shares during the period. Gladius Capital Management LP acquired a new stake in Avantor during the 4th quarter worth about $42,000. Montag A & Associates Inc. acquired a new stake in Avantor during the 4th quarter worth about $43,000. Finally, TFO Wealth Partners LLC boosted its position in Avantor by 203,100.0% during the 4th quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock worth $46,000 after acquiring an additional 2,031 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on AVTR. Deutsche Bank Aktiengesellschaft raised their price objective on Avantor from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Thursday, April 18th. Evercore ISI lifted their price target on Avantor from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Barclays reduced their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday. Finally, Robert W. Baird reduced their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, April 29th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $26.36.

Avantor Stock Performance

Shares of Avantor stock traded down $0.22 on Friday, reaching $21.20. The stock had a trading volume of 9,536,567 shares, compared to its average volume of 6,872,663. The business’s 50-day moving average price is $23.73 and its two-hundred day moving average price is $23.79. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.05 and a current ratio of 1.61. Avantor, Inc. has a fifty-two week low of $16.63 and a fifty-two week high of $26.16. The stock has a market cap of $14.40 billion, a P/E ratio of 54.36, a price-to-earnings-growth ratio of 2.17 and a beta of 1.35.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Friday, April 26th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.02. Avantor had a net margin of 3.79% and a return on equity of 13.01%. The business had revenue of $1.68 billion during the quarter, compared to analysts’ expectations of $1.68 billion. During the same period in the previous year, the company earned $0.29 earnings per share. Avantor’s revenue for the quarter was down 5.6% on a year-over-year basis. On average, sell-side analysts forecast that Avantor, Inc. will post 1.01 EPS for the current year.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.